CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 86 people enrolled
- Started
- 15 Sept 2023
- Ended
- 27 Feb 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Ciclosporin
- Avatrombopag
- Anti-Human Thymocyte Immunoglobulin, Rabbit
- Record updated
- 30 April 2025
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients with newly diagnosed severe aplastic anemia, aged greater than 60 years
- Patients met the diagnostic criteria of severe aplastic anemia (SAA)
- Complete all screening assessments as outlined in the test protocol
- Without or with no more than 1 month treatment of ciclosporine, tacrolimus, glucocortocoid, or TPO-RAs
- Agree to sign the informed consent form
Who cannot take part
- Patients with previous history of hematopoietic stem cell transplantation
- Patients with previous history of thrombosis in 1 year
- Patients with concurrent malignancy
- Known diagnosis of congenital hematopoietic failure disorders (e.g. Fanconi anemia) and other causes of cytopenia
- Patients with uncontrolled bleeding and/or infection despite standard treatment
- Patients with severe heart, liver or renal disease
- Abnormal renal function: creatinine > 1.2 normal upper limit, albumin < 0.9 normal lower limit, or CLcr < 30 ml/min
- Abnormal liver function: transaminase > 2.5 normal upper limit, or tota bilirubin > 2.5 normal upper limit
- Those who are considered unsuitable for enrollment by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, prospective, randonmized study. Our previous retrospective study showed that for SAA patients who were intolerant to ATG, CsA+ eltrombopag (EPAG) had similar efficacy to CsA+ATG+EPAG. Since the action mechanism of AVA and EPAG is not exactly the same, and the metabolic level of the elderly is not the same as that of younger patients, it is unknown whether there are predictive factors of efficacy in the treatment of AVA. We wondered whether CsA+AVA could achieve an efficacy similar to CsA+ATG+AVA in the Elderly. Meanwhile, to explore the predictive factors of efficacy, to find out a safe and effective treatment strategy for the Elderly.
The 2 groups in the trial
- CsA+ATG+AVATreatment being tested
Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Anti-human thymocyte: rabbit anti-human thymocyte globulin (r-ATG 3mg/kg/d) was administered intravenously for 5 days; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
Treatment: Ciclosporin, Avatrombopag, and Anti-Human Thymocyte Immunoglobulin, Rabbit
- CsA+AVATreatment being tested
Ciclosporine: 3-5 mg/kg/d orally, with ciclosporine trough concentrations maintained at 100-200 ng/ml for 3 months to achieve maximum efficacy and then tapered; Avatrombopag:60 mg/d orally, for a total of 24 weeks. Adjust the dose according to the platelet counts of patients.
Treatment: Ciclosporin and Avatrombopag
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ciclosporin + Antithymocyte Immunoglobulin + Avatrombpag Versus Ciclosporin + Avatrombpag for the Treatment of Severe Aplastic Anemia in the Elderly
- Record updated
- 30 April 2025